BEGIN:VCALENDAR
VERSION:2.0
PRODID:-// - ECPv6.6.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.biomed.cas.cz
X-WR-CALDESC:Akce na 
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Prague
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Prague:20250324T140000
DTEND;TZID=Europe/Prague:20250324T150000
DTSTAMP:20260420T075352
CREATED:20250305T115621Z
LAST-MODIFIED:20250305T115621Z
UID:2317-1742824800-1742828400@www.biomed.cas.cz
SUMMARY:Přednáška pro nevědce a nevědkyně - V. Hořejší
DESCRIPTION:Poučení z covidové epidemie – co dělat příště jinak \nCovidová krize v letech 2020-2022 výrazně zasáhla do životů nás všech. Co se udělalo dobře a co naopak špatně? Jak obstáli občané\, politici\, vědci a zdravotníci? Jak je možné\, že se americkým ministrem zdravotnictví stává výrazný antivaxer a šiřitel „fejků“? Pochází covidový virus z přírody nebo z laboratoře? Pomohou nám získané zkušenosti při příští epidemii\, která jistě někdy přijde? \nZajímavých otázek je mnoho… \n 
URL:https://www.biomed.cas.cz/event/prednaska-pro-nevedce-a-nevedkyne-v-horejsi/
LOCATION:Posluchárna Milana Haška / Milan Hašek Auditorium
ORGANIZER;CN="%C3%9AMG":MAILTO:leona.krausova@img.cas.cz
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Prague:20250324T150000
DTEND;TZID=Europe/Prague:20250324T160000
DTSTAMP:20260420T075352
CREATED:20250319T135232Z
LAST-MODIFIED:20250319T135232Z
UID:2341-1742828400-1742832000@www.biomed.cas.cz
SUMMARY:Lectures – Laboratory of Experimental Hypertension\, IPHYS
DESCRIPTION:Silvie Hojná: Anorexigenic neuropeptides in the treatment of obesity \nObesity and its complications have reached epidemic proportions. Therefore\, finding new\, more effective drugs for the treatment of obesity without side effects is a major challenge. Natural anorexigenic neuropeptides have this potential\, but their major disadvantage is their low stability in plasma and inability to cross the blood-brain barrier (BBB) after peripheral administration. One strategy to develop peptidic drugs is based on peptide lipidization. This modification leads to increased stability and half-life of the peptide in the organism and allows its application in the periphery because lipidized peptides are able to cross the BBB. In Monday’s seminar\, you will hear the full story of the development of anorexigenic analogs of prolactin-releasing peptide (PrRP)\, including their implications not only for the treatment of obesity\, but also for their other potential applications. \nMahak Arora: Role of mTOR in cardiometabolic dysfunction \nCardiometabolic disorders (CMDs) such as hypertension\, diabetes and obesity are associated with damage to key organs such as the heart\, liver and kidneys. The mammalian target of rapamycin (mTOR) signaling pathway\, which is critical for cell metabolism and growth\, is often dysregulated in these diseases. In a mouse model of steatohepatitis\, the mTOR inhibitor KU-0063794 ameliorated oxidative stress\, reduced liver triglycerides and downregulated TNF-alpha mRNA by altering mTOR signaling. Recent pilot studies in high-fat fed SHR rats treated with empagliflozin and salt-sensitive Dahl rats exposed to high or low salt diet showed significant changes in mTOR-related genes such as mtor\, akt\, pgc1a\, srebp\, etc. in liver and kidney. These results suggest that mTOR plays a key role in the regulation of cardiometabolic functions
URL:https://www.biomed.cas.cz/event/lectures-laboratory-of-experimental-hypertension-iphys/
LOCATION:Kinosal\, Vídeňská 1083\, Praha
END:VEVENT
END:VCALENDAR